RhAPPcast: Navigating the Complexities: IL-17 Inhibitors and IBD Risk

Join Amanda Mixon, PA-C, President of RhAPP, and Candace Ryan, PA-C, as they explore the evolving discussion around IL-17 inhibitors and their potential impact on inflammatory bowel disease (IBD) in this episode of RhAPPcast.IL-17 inhibitors have revolutionized the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis, offering targeted therapy for chronic inflammatory conditions. However, emerging data suggest that IL-17 inhibition may influence gut inflammation, raising important considerations for clinicians managing patients with concurrent or potential IBD. This discussion reviews the latest clinical trial data, meta-analyses, and real-world evidence to provide clarity on the relationship between IL-17 blockade and IBD development.Key takeaways include identifying at-risk patients, implementing proactive monitoring strategies, and optimizing treatment selection for those with overlapping rheumatic and gastrointestinal conditions. Learn best practices for prescribing, monitoring, and patient education to maximize therapeutic outcomes while mitigating risks.For the latest expert discussions, medication reviews, and clinical insights into rheumatic disease management, visit RhAPP.org or download the RhAPP ACE App.